三诺生物收盘下跌2.12%，滚动市盈率38.62倍，总市值122.61亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sanofi Biologicals, particularly its stock performance and industry comparisons [1][2] - As of June 26, the stock price of Sanofi Biologicals closed at 21.73 yuan, down 2.12%, with a rolling PE ratio of 38.62 times and a total market capitalization of 12.261 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 49.45 times and a median of 35.92 times, Sanofi Biologicals ranks 81st in terms of PE ratio [1][2] Group 2 - The main business of Sanofi Biologicals is the production and sale of blood glucose monitoring systems, along with related products such as diabetes nutrition and care products, blood lipid testing systems, and blood pressure monitors [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 1.042 billion yuan, a year-on-year increase of 2.76%, while net profit was 72.115 million yuan, reflecting a year-on-year decrease of 10.90% [1] - The gross profit margin for the company stands at 48.69% [1]